Legal & General Group
BBNX

Legal & General Group’s Beta Bionics BBNX Stock Holding History

Legal & General Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62K Sell
3,955
-2,081
-34% -$24.8K ﹤0.01% 2708
2026
Q1 		$60.5K Sell
6,036
-498
-8% -$7.37K ﹤0.01% 2650
2025
Q4 		$199K Sell
6,534
-100
-2% -$2.67K ﹤0.01% 2583
2025
Q3 		$132K Buy
6,634
+2,658
+67% +$46.7K ﹤0.01% 2622
2025
Q2 		$57.9K Buy
3,976
+2,639
+197% +$37.4K ﹤0.01% 2693
2025
Q1 		$16.4K Buy
+1,337
New +$24.9K ﹤0.01% 3018

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Legal & General Group's BBNX Position: Q2 2026 in Review

Legal & General Group reduced its Beta Bionics (BBNX) stake by 34% in Q2 2026, selling an estimated $24.8K and leaving 3,955 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #2708.

Legal & General Group first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $199K in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Legal & General Group held 3,955 shares of Beta Bionics worth $62K as of Q2 2026.
  • Legal & General Group sold 2,081 Beta Bionics shares in Q2 2026, an estimated $24.8K.
  • Beta Bionics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2708 holding.
  • Legal & General Group first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • Legal & General Group's Beta Bionics position peaked at $199K in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.